5 Stocks That Have the Potential to Rise 1000%

3. Ascentage Pharma Group International (NASDAQ:AAPG)

On May 31, 2026, Ascentage Pharma Group International (NASDAQ:AAPG) announced Phase Ib results evaluating olverembatinib in combination with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. The data were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology Annual Meeting. Ascentage Pharma said 91% of patients achieved complete response or complete response with incomplete hematologic recovery, while 67% achieved BCR::ABL1 negativity by PCR and 80% achieved MRD negativity by flow cytometry.

Also on May 31, Ascentage Pharma Group International (NASDAQ:AAPG) presented its first dataset for alrizomadlin, an MDM2-p53 inhibitor, as monotherapy or in combination with lisaftoclax in pediatric patients with relapsed/metastatic rhabdomyosarcoma or other soft-tissue sarcomas. In the monotherapy arm, one patient with refractory RMS achieved a complete response. In the combination arm, the ORR was 23.5% among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, while the disease control rate was 70.6%.

In April, Deutsche Bank initiated coverage of Ascentage Pharma Group International (NASDAQ:AAPG) with a Buy rating and a $40 price target. Deutsche Bank cited two “de-risked, commercially validated” mechanisms in olverembatinib and lisaftoclax, and said lisaftoclax is positioned for continued commercial traction in China.

Ascentage Pharma Group International (NASDAQ:AAPG) develops therapies for cancers, chronic hepatitis B virus, and age-related diseases in Mainland China.